Login to Your Account


'Potential for this to be broadly active'

Just last month, Australia's Viralytics Ltd. was marching to completion on its phase Ib immunotherapy programs of lead candidate Cavatak after landing a A$29.6 million (US$23.9 million) private placement with China's Lepu Medical Group.

more »


Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.

READ MORE »

Opinion


Partners in Focus